DiaMedica Therapeutics Inc. cotiza a 8.20 USD y tiene una capitalización bursátil de $442M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of a…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.19 | $-0.19 | $-0.17 |
| Estimado | $-0.21 | $-0.20 | $-0.18 | $-0.18 |
| Sorpresa | — | +5.0% | -5.6% | +5.6% |
| Métrica | DMAC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -58.4% | -40.4% | -18.0% |
| ROA | -53.4% | -32.0% | -21.4% |
| Current Ratio | 11.81 | 2.84 | +8.97 |
| Debt / Equity | — | 0.28 | — |